Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia

Immunology

Volumn 99, Issue 1, 2000, Pages 8-15

  Colombo, B M ^b   Lacave, R ^c   Pioche Durieu, C ^a   Masurier, C ^a   Lemoine, F M ^a   Guigon, M ^a   Klatzmann, D ^a,d  

^a CNRS   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c HÔPITAL TENON   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELLULAR IMMUNITY; DENDRITIC CELL; FEMALE; IMMUNOSTIMULATION; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIGENS, CD4; CANCER VACCINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED DBA; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0004382672     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2000.00933.x     Document Type: Article

References (40)

1. 1. Boon T., Cerottini J.C., Van den Eynde B., Van der Bruggen P. & Van Pel A. (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12, 337.
2. 2. Greiner J.W., Guadagni F., Noguchi P. et al. (1987) Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235, 895.
3. 3. Mulé J.J., McIntosh J.K., Jablons D.M. & Rosenberg S.A. (1990) Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 171, 629.
4. 4. Smith K.A. (1993) Lowest dose interleukin-2 immunotherapy. Blood 81, 1414.
5. 5. Fisher B., Packard B.S., Read E.J. et al. (1989) Tumor localization of adoptively transferred indium-III labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7, 250.
6. 6. Rosenberg S.A., Spiess P. & Lafreniere R. (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318.
7. 7. Chen L., Ashe S., Brady W.A. et al. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093.
8. 8. Schmidt-Wolf G.D. & Schmidt-Wolf I.G.H. (1995) Cytokines and gene therapy. Immunol Today 16, 173.
9. 9. Steinman R.M. (1996) Dendritic cells and immune-based therapies. Exp Hematol 24, 859.
10. 10. Troy A.J. & Hart D.N.J. (1997) Dendritic cells and cancer: progress toward a new cellular therapy. J Hematother 6, 523.
11. 11. Steinman R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9, 271.
12. 12. Banchereau J. & Steinman R.M. (1998) Dendritic cells and the control of immunity. Nature 392, 245.
13. 13. Mayordomo J.I., Zorina T., Storkus W.J. et al. (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1, 1297.
14. 14. Zitvogel L., Mayordomo J.I., Tjandrawan T. et al. (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183, 87.
15. 15. Paglia P., Chiodoni C., Rodolfo M. & Colombo M.P. (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183, 317.
16. 16. Boczkowski D., Nair S.K., Snyder D. & Gilboa E. (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184, 465.
17. 17. Nair S.K., Snyder D., Rouse B.T. & Gilboa E. (1997) Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70, 706.
18. 18. Ashley D.M., Faiola B., Nair S. et al. (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186, 1177.
19. 19. Mukherji B., Chakraborty N.G., Yamasaki S. et al. (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-puised autologous antigen presenting cells. Proc Natl Acad Sci USA 92, 8078.
20. 20. Hsu F.J., Benike C., Fagnoni F. et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2, 52.
21. 21. Nestle F.O., Alijagic S., Gillet M. et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4, 328.
22. 22. Reichardt V.L., Okada C.Y., Liso A. et al. (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 93, 2411.
23. 23. Rabbitts T.H. (1994) Chromosomal translocations in human cancer. Nature 372, 143.
24. 24. Gedde-Dahl T., Fossum B., Eriksen J.A., Thorsby E. & Gaudernack G. (1993) T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol 23, 754.
25. 25. Houbiers J.G.A., Nijman H.W., Van der Burg S.H. et al. (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Jmmunol 23, 2072.
26. 26. Kwak L.W., Campbell M.J., Czerwinski D.K., Hart S., Miller R.A. & Levy R. (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New Engl J Med 327, 1209.
27. 27. Nelson E.L., Li X., Hsu F.J. et al. (1996) Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, nonHodgkin's lymphoma. Blood 88, 580.
28. 28. Kwak L.W., Taub D.D., Duffey P.L. et al. (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345, 1016.
29. 29. Porgador A. & Gilboa E. (1995) Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182, 255.
30. 30. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T. & Falo L.D. (1996) Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 183, 283.
31. 31. Flamand V., Sornasse T., Thielemans K. et al. (1994) Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24, 605.
32. 32. Wang B., Merva M., Dang K. et al. (1995) Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Hum Gene Ther 6, 407.
33. 33. Masurier C., Pioche-Durieu C., Colombo B.M. et al. (1999) Immunophenotypical and functional heterogeneity of dendritic cells generated from murine bone marrow cultured with different cytokine combinations: implications for anti-tumoural cell therapy. Immunology 96, 569.
34. 34. Idziorek T. & Klatzmann D. (1991) Functional expression of the CD4 protein after cross-linking to red blood cells with a bifunctional reagent. Biochim Biophys Ada 1062, 39.
35. 35. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M. & Strober W. (1994) Current Protocols in Immunology (Series ed. R. Coico). John Wiley & Sons Inc.
36. 36. Chams V., Jouault T., Fenouillet E., Gluckman J.C. & Klatzmann D. (1988) Detection of anti-CD4 autoantibodies in the sera of HIV-infected patients using recombinant soluble CD4 molecules. AIDS 2, 353.
37. 37. Todaro G.J., Larco J.E., Fryling C., Johnson P.A. & Sporn M.B. (1981) Transforming growth factors (TGFs): properties and possible mechanisms of action. J Supramol Struct Cell Biochem 15, 287.
38. 38. Zhang Y., Zhang Y.Y., Ogata M. et al. (1999) Transforming growth factor-beta 1 polarizes murine hematopoietic progenitor cells to generate Langerhans cell-like dendritic cells through a monocyte/macrophage differentiation pathway. Blood 93, 1208.
39. 39. Geissmann F., Revy P., Regnault A. et al. (1999) TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 162, 4567.
40. 40. Qin Z., Richter G., Schüler T., Ibe S., Cao X. & Blankenstein T. (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4, 627.